Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.61 |
| ▸ | JAK1 | P23458 | 2/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.61 |
| ▸ | MET | P08581 | 7/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
| ▸ | MST1R | Q04912 | 1/20 | 0.53 |
| ▸ | MAP4K3 | Q8IVH8 | 4/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18861159 | 0.85 | MET (0.57) | JAK2JAK1JAK3METABL1 | |
| SCHEMBL30387867 | 0.85 | MET (0.57) | JAK2JAK1JAK3METABL1 | |
| SCHEMBL29914439 | 0.84 | MET (0.55) | JAK2JAK1JAK3METFGFR1 | |
| SCHEMBL29631682 | 0.81 | MET (0.64) | JAK2JAK1JAK3MET | |
| SCHEMBL28346361 | 0.81 | MET (0.64) | JAK2JAK1JAK3MET | |
| SCHEMBL18860384 | 0.79 | MET (0.50) | JAK2JAK1JAK3METABL1 | |
| SCHEMBL16758557 | 0.78 | MET (0.63) | JAK2JAK1JAK3MET | |
| SCHEMBL16758514 | 0.78 | MET (0.63) | JAK2JAK1JAK3MET | |
| SCHEMBL29964349 | 0.78 | JAK2 (0.52) | JAK2JAK1JAK3METABL1 | |
| SCHEMBL16758516 | 0.78 | MET (0.58) | JAK2JAK1JAK3METABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | JAK2 333/4885JAK1 241/4885JAK3 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.